Learn how to self-administer SCIg at home for primary immunodeficiency. Tips on preparation, reducing pain, managing ...

Explore the complexities of modern oncology, including precision medicine, CAR T-cell therapies, and challenges in breast ...

NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the plan to initiate a Phase 2 clinical trial evaluating monoclonal antibody ...

Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 - Genmab A/S (Nasdaq: GMAB) ...

Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, ...

Cone Health rethinking infusion aligns services, standardizes workflows and boosts capacity across oncology and non-oncology sites.

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...

Preliminary total global full year 2025 revenue of approximately $616 millionPreliminary BRIUMVI U.S. fourth quarter and full year 2025 net ...

AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to ...

Five-year results suggest Hemgenix may help reduce bleeding in hemophilia B. Many patients needed far fewer factor IX infusions after treatment. Most maintained stable factor IX levels, with generally ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted priority review to veligrotug for the treatment of thyroid eye disease, according to a press ...